Volume 15, Number 9—September 2009
Salmonella enterica Serovar Typhi with CTX-M β-Lactamase, Germany
Highlight and copy the desired format.
|EID||Pfeifer Y, Matten J, Rabsch W. Salmonella enterica Serovar Typhi with CTX-M β-Lactamase, Germany. Emerg Infect Dis. 2009;15(9):1533-1535. https://dx.doi.org/10.3201/eid1509.090567|
|AMA||Pfeifer Y, Matten J, Rabsch W. Salmonella enterica Serovar Typhi with CTX-M β-Lactamase, Germany. Emerging Infectious Diseases. 2009;15(9):1533-1535. doi:10.3201/eid1509.090567.|
|APA||Pfeifer, Y., Matten, J., & Rabsch, W. (2009). Salmonella enterica Serovar Typhi with CTX-M β-Lactamase, Germany. Emerging Infectious Diseases, 15(9), 1533-1535. https://dx.doi.org/10.3201/eid1509.090567.|
To the Editor: Infection with Salmonella enterica serovar Typhi, the causative agent of typhoid fever, is an acute systemic illness with a high proportion of illness and deaths, especially in developing countries. In Europe, S. enterica ser. Typhi infections occur among travelers returning from disease-endemic areas. After emergence of multidrug-resistant S. enterica ser. Typhi strains that confer resistance to chloramphenicol, trimethoprim, and ampicillin, quinolones have become the primary drugs for treatment (1). Here we report the isolation of a CTX-M–producing S. enterica ser. Typhi in Germany.
We isolated S. enterica ser. Typhi from blood and feces specimens from a 30-year-old Iraqi woman who was admitted to the hospital in Cologne in August 2008. The patient was febrile, dizzy, and had epigastric pain and headache. The symptoms began 2 weeks earlier, after she had returned from a month-long visit to her relatives in Sulaymaniya, the capital of As Sulaymaniyah Governorate in the northeastern Iraqi Kurdistan region. The interview indicated that the same symptoms had developed in other family members in Iraq. The patient was treated successfully with meropenem (1 g 3×/day) for 2 weeks, and no relapse was observed in a follow-up period of 6 months.
The isolated strain was identified as S. enterica ser. Typhi with the VITEK2 system (VITEK2 GN-card; bioMérieux, Brussels, Belgium) and by slide agglutination with Salmonella antisera (SIFIN, Berlin, Germany) in accordance with the Kauffmann-White scheme. By using Vi-phage typing according to the International Federation for Enteric Phage Typing (L.R. Ward, pers. comm.), the strain was classified as S. enterica ser. Typhi Vi-phage type E9. Antimicrobial drug susceptibilities were determined according to the guidelines of the Clinical Laboratory Standards Institute with the VITEK2 AST-N021 card and Etest (bioMérieux). The extended-spectrum β-lactamase (ESBL) phenotype was confirmed with a combined disk diffusion test (MASTDISCS ID, Mast Diagnostica GmbH, Germany). PCR and sequence analyses were performed with universal primers for the ESBL genes blaCTX-M, blaTEM, and blaSHV as described previously (2). Primer CTX-M-F 5′-TTCGTCTCTTCCAGAATAAGG-3′ and primer CTX-M-R 5'-CAGCACTTTTGCCGTCTAAG-3′ were used for sequencing the entire blaCTX-M gene. Investigation of the CTX-M environment was performed with primers IS26-F (5′-GCCTGGTAAGCAGAGTTTTTG-3′) and IS26-CTX-R (5′-ACAGCGGCACACTTCCTAAC-3′). The presence of plasmid-mediated quinolone resistance genes (qnr) was determined by PCR and sequencing of qnrB (3), qnrS (primer F, 5′-CGGCACCACAACTTTTCAC-3′; primer R, 5′-CAACAATACCCAGTGCTTCG-3′), and qnrA (primer F, 5′-ATTTCTCACGCCAGGATTTG-3′; primer R, 5′-CGGCAAAGGTTAGGTCACAG-3′). In addition, the nucleotide sequences of the quinolone resistance-determining regions of the gyrA, gyrB, parC, and parE genes were determined as previously described (4). Transfer of β-lactam resistance was tested by broth mating assays with a sodium azide–resistant Escherichia coli J53 recipient. Selection of transconjugants was performed on Mueller-Hinton agar plates that contained sodium azide (200 μg/mL) and ampicillin (100 μg/mL). We isolated the plasmid DNA of donor and transconjugants using the QIAGEN Plasmid Mini Kit (QIAGEN, Hilden, Germany).
Phenotypically, the strain was resistant to ampicillin, ampicillin/sulbactam, piperacillin, cefotaxime, ceftazidime, cefepime, chloramphenicol, streptomycin, trimethoprim/sulfamethoxazole, azithromycin, and nalidixic acid. A reduced susceptibility to ciprofloxacin was detected (MICCIP = 1 μg/mL). The isolate was susceptible to imipenem, meropenem, gentamicin, tobramycin, and amikacin. PCR and sequence analyses displayed the presence of blaCTX-M-15, blaTEM-1 and the qnrB2 gene. We found an amino acid substitution in gyrA gene (83-Ser→Phe). No mutations were identified in the gyrB, parC, and parE genes. Sequencing of the insertion element (IS)26-F/R amplification product showed the location of IS26 transposase A gene (tnpA), followed by a truncated ISEcp1 mobile element upstream of the blaCTX-M-15 gene. By conjugation, 1 plasmid of ≈50 kbp was successfully transferred into an E. coli J53 recipient (Figure). PCR-based replicon typing (5) showed an IncN–related plasmid. The E. coli J53 transconjugant mediated resistance to ampicillin, cefotaxime, ceftazidime, cefepime, trimethoprim/sulfamethazole, nalidixic acid and showed reduced susceptibility to ciprofloxacin (MIC = 0.5 μg/mL). Also, in the transconjugant, the blaCTX-M-15 and qnrB2 genes were identified by PCR.
ESBL-producing non-Typhi serotypes of S. enterica are an increasing problem worldwide. In Europe and Asia, CTX-M-group ESBLs are prevalent in S. enterica, and in North America, domestically acquired CTX-M ESBLs were recently identified in S. enterica ser. Typhimurium (6). In S. enterica ser. Typhi, reports of ESBLs have been rare. The CTX-M-15 type that we found has been reported only once previously in S. enterica ser. Typhi from Indian patients hospitalized in Kuwait (7). In addition to cephalosporin resistance mediated by ESBLs, the reduced susceptibility to quinolones in S. enterica is of concern. In the study isolate, this reduced susceptibility was due to a known mutation 83-Ser→Phe in gyrA (8) and the acquisition of a qnB2 gene. Plasmid-mediated Qnr determinants have been identified in S. enterica of different non-Typhi serovars (9), whereas in S. enterica ser. Typhi, only mutations in gyrase and topoisomerase genes leading to quinolone resistance had been observed previously (8).
In our isolate of S. enterica ser. Typhi that contained blaCTX-15 and qnrB2, resistance to cephalosporins as well as the reduced quinolone susceptibility was easily transferable by conjugation into E. coli. This occurrence is alarming because the dissemination of such strains with acquired resistances will further limit the therapeutic options for treatment of typhoid fever.
We thank George A. Jacoby for providing the E. coli J53 Azir strain, Alessandra Carattoli for supplying Inc group reference strains, and Jean M. Whichard for critical reading. We extend special thanks to Dagmar Busse and Bettina Leiste for phage typing and phenotypical analysis.
This work was funded by the Ministry of Health, Germany.
- Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR. Multidrug-resistant and extended-spectrum β-lactamase (ESBL)–producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis. 2006;10:434–8.
- Gröbner S, Linke D, Schütz W, Fladerer C, Madlung J, Autenrieth IB, Emergence of carbapenem–non-susceptible extended-spectrum β-lactamase (ESBL)–producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. J Med Microbiol. 2009;58:912–22.
- Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, Robicsek A, qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother. 2006;50:1178–82.
- Giraud E, Brisabois A, Martel JL, Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother. 1999;43:2131–7.
- Carattoli A, Miriagou V, Bertini A, Loli A, Colinon C, Villa L, Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerg Infect Dis. 2006;12:1145–8.
- Sjölund M, Yam J, Schwenk J, Joyce K, Medalla F, Barzilay E, Human Salmonella infection yielding CTX-M beta-lactamase, United States. Emerg Infect Dis. 2008;14:1957–9.
- Rotimi VO, Jamal W, Pal T, Sovenned A, Albert MJ. Emergence of CTX-M-15 type extended-spectrum beta-lactamase-producing Salmonella spp. in Kuwait and the United Arab Emirates. J Med Microbiol. 2008;57:881–6.
- Capoor MR, Nair D, Walia NS, Routela RS, Grover SS, Deb M, Molecular analysis of high-level ciprofloxacin resistance in Salmonella enterica serovar Typhi and S. Paratyphi A: need to expand the QRDR region? Epidemiol Infect. 2009;137:871–8.
- Gay K, Robicsek A, Strahilevitz J, Park CH, Jacoby G, Barrett TJ, Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis. 2006;43:297–304.
FigureCite This Article
- Page created: December 07, 2010
- Page last updated: December 07, 2010
- Page last reviewed: December 07, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)